UK-based medical technology firm LivaNova has commercially introduced Platinum, a new range of implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds).


Platinum device are available in different sizes ranging from 31cc to 33cc. The Ergoform design of the can will facilitate the implant procedure and improve patient comfort.

The devices also incorporate therapeutic functions such as arrhythmia discrimination algorithm PARAD, and pacing mode SafeR that preserves natural heart conduction.

It also includes hemodynamic sensor SonR, which automatically enhances CRT settings.

LivaNova CRM business unit president Stefano Di Lullo said: "Platinum’s unsurpassed longevity will benefit all patients, both those who, thanks to the efforts of the medical community, are living longer as well as those who are receiving their first device at a younger age.

"Platinum’s outstanding longevity together with its small size and proven therapeutic features reflect our commitment to developing breakthrough technologies that provide the very best care to patients."

According to the company, the service life is projected to last over 14 years for the single-chamber ICD model, over 13 years for the dual-chamber ICD model, and over 10 years for CRT-D devices, in standard functioning conditions.

With operations in around 100 countries, LivaNova has three business units such as cardiac rhythm management, cardiac surgery and neuromodulation.

Image: Platinium, a new range of implantable cardiac defibrillators and CRT-D devices. Photo: courtesy of Business Wire.